Videos

Now that we're in an era of personalized medicine, patients should not look at statistics and immediately think that they will determine their fate, says Tom Stockwell, patient navigator at the Fibrolamellar Cancer Foundation.

Marina Chiara Garassino, M.D., talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Carole Brennan Miller, M.D., head of the Cancer Institute at Saint Agnes Hospital, explains what makes people with myeloproliferative neoplasms (MPNs) unique, and why she finds it interesting to work with them.

A myeloproliferative neoplasm survivor and advocate offers advice on how loved ones can support a patient with cancer.

Cristiana Sessa, M.D., of the Oncology Institute of Southern Switzerland, discusses the evolution of how PARP inhibitors are used to treat ovarian cancer.

Susan Leclair, Ph.D., CLS (NCA), retired lab professor at University of Massachusetts, Dartmouth, discusses how moderating an online forum for patients with myeloproliferative neoplasms (MPNs) has inspired her.

Catriona Jamieson, M.D., Ph.D., Professor of Medicine, University of California, San Diego Health Moores Cancer Center, addresses a common myth about clinical trials.

Luis A. Diaz, M.D., head of the division of Solid Tumors at Memorial Sloan Kettering Cancer Center, discusses response rates in patients with microsatellite instability-high (MSI-H) or NTRK fusion gastrointestinal (GI) cancers.